BIOXYTRAN, INC 8-K

What Happened

• Bioxytran, Inc. (ticker: BIXT) filed a Form 8‑K on March 2, 2026 (Accession No. 0001493152-26-008475) under Item 8.01 to announce positive Phase 1b/2a clinical study results for ProLectin‑M, described as a broad‑range antiviral for mild to moderate COVID‑19. The company attached a press release announcing the results as Exhibit 99.1.

Key Details

• Filing date: March 2, 2026; Form 8‑K reported under Item 8.01 (Other Events).
• Clinical update: Positive results from a Phase 1b/2a study for ProLectin‑M in mild to moderate COVID‑19 (announcement described the drug as a broad‑range antiviral).
• Disclosure format: Results were disclosed via a press release titled “Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin‑M…” filed as Exhibit 99.1 to the 8‑K.
• Scope of this 8‑K: The filing is an event/clinical update only — it does not report earnings, financial statements, executive changes, or M&A activity.

Why It Matters

• This filing is a clinical development milestone for Bioxytran’s ProLectin‑M program; positive Phase 1b/2a results can be viewed as early evidence that the drug advances beyond initial safety/early efficacy testing.
• For investors, the announcement provides a factual update on pipeline progress. Investors who follow Bioxytran should read the attached press release (Exhibit 99.1) for full study details and await any future regulatory, clinical or financial disclosures that provide additional data or next steps.